Extended Data Fig. 10. Klg-1 - derived dormant transplant forms immune-privileged tissue that protects allogeneic islets in a mouse model of diabetes.
a. Normoglycemic range in wild type FVB/NJ mice is between 4-11 mmol/L (brown highlighted region). b. FVB/NJ recipients were treated with STZ (d-7), a beta-cell cytotoxic agent, leading to the rapid development of hyperglycemia (red highlighted region). Seven days later, islets isolated from allogeneic C3H/HeJ donor mice were harvested and transplanted (d0) underneath the kidney capsule of STZ-treated FVB/NJ recipients. Normoglycemia was only restored short term, indicating the rejection of the allogeneic islets. c. Dormant transplants derived from uncloaked FS mESCs in B6 mice. Recipients were then treated with STZ to induce hyperglycemia, and 7 days later (d0), islets from allogeneic C3H mice were grafted into the tissue that rapidly returned to stable normoglycemia (n = 3 recipients). The hyperglycemia, however, returned after a few weeks, indicating the rejection of the allogeneic islets. d. Dormant transplants derived from Klg-1 cell line in B6 mice. Then STZ-induced hyperglycemia was treated with allogeneic C3H islets grafted into the transplants (n = 3 recipients). The animals then rapidly returned to stable normoglycemia that lasted until the transplant surgically removed.